CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
StockNews.AI · 3 hours
AI Summary
FDA reviewed CalciMedica's KOURAGE amendment and interim safety data, with no comments, allowing continued Auxora dosing. The March amendments address design issues and confirm SAEs are not drug-related, reducing setback risk and keeping a potential pancreatitis pivotal program on track for 3Q26.
Sentiment Rationale
No FDA comments reduce immediate hold risk; near-term catalysts include continued dosing and Q3 2026 pancreatitis-program feedback; potential upside if pivotal-path progress remains on track.
Trading Thesis
CalciMedica could see near-term upside as dosing resumes; pancreatitis program feedback due in 3Q26.
Market-Moving
- FDA did not raise comments, reducing near-term clinical hold risk.
- FDA feedback on pancreatitis pivotal program expected in Q3 2026.
- KOURAGE design amendments may shorten path to pivotal trials if approved.
- Positive safety assessment reinforces Auxora's development path.
Key Facts
- FDA reviewed KOURAGE protocol amendment and interim safety data; no comments.
- Enrollment pause in January 2026 lifted; no clinical hold.
- March 2026 amendment refined inclusion criteria and stratification.
- SAEs were not drug-related and align with prior Auxora data.
- FDA no comments; expects pancreatitis pivotal program feedback in Q3 2026.
Companies Mentioned
- CalciMedica, Inc. (CALC): Positive regulatory progress; FDA review found no comments, enabling continued dosing; potential pancreatitis pivotal program.
- Auxora (N/A): CalciMedica's intravenous CRAC inhibitor; continued dosing now supported by FDA review.
- KOURAGE Trial (N/A): Phase 2 trial in AKI with AHRF; protocol amendments and safety data drive development path.
Corporate Developments
Category: Corporate Developments. regulatory progress and trial-design changes can influence CalciMedica's development timeline and valuation.